Boston, MA 04\/09\/2014 (wallstreetpr) –\u00a0Any breakthrough in the field of medicine, especially, incurable or hard-to-cure diseases generate hype. It is the case with the breakthrough drug from Merck & Co., Inc. (NYSE:MRK)<\/b> called the MK-3475 that provides efficient results in the treatment of non-small cell lung cancer (NSCLC). It also is effective in treating advanced melanoma. This drug was presented in the annual meeting of the American Association for Cancer Research.<\/p>\n
The drug seems to have a 40% response rate on the solid tumors. The effect shown by the drug on tumor type positivePD-L1 was 49%, much higher than the 13% on those with negative tumors of the same kind. It was also reported as a finding that PD-L1 tumors are found among 71% of advanced melanoma patients.<\/p>\n
Study Findings<\/b><\/p>\n
The early findings on MK-3475 in 129 treatments, that could be evaluated, were also shown during the meeting. The overall response rate of the NSCLC population, in the advanced stage, was calculated to be 19%, where another study shows that about 45% of them also have tumor type of positive PD-L1. Beside the melanoma, along with the NSCLC, the drug is also is examined and tested for oncological problems in the bladder, prostate, pancreas, gastric, head and neck, breast, etc. There are several collaborations with Amgen, Incyte and Pfizer which Merck & Co., Inc. (NYSE:MRK) has for evaluation of the various grouping regimens of MK-3475.<\/p>\n
Future expectations<\/b><\/p>\n
There are no guarantees with the products in the pipeline because if the underlying assumptions turn inaccurate then the entire research will be down the drain. The company\u2019s ability to accurately predict the market volatility, manufacturing issues, financial intricacies and the overall risk associated will determine the effectiveness of the products and to keep them from being embroiled in some litigation related to patent or regulatory actions. So the company has cautiously refused to launch it in the prime time supply until further tests are done on it. Merck & Co., Inc. (NYSE:MRK) is currently trading at $56.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 04\/09\/2014 (wallstreetpr) –\u00a0Any breakthrough in the field of medicine, especially, incurable or hard-to-cure diseases generate hype. It is the case with the breakthrough […]<\/p>\n","protected":false},"author":32,"featured_media":15692,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1683,1123],"stock_ticker":[],"class_list":["post-19194","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-merck-co-inc-nysemrk","tag-nysemrk","entry"],"acf":[],"yoast_head":"\n